Compare WLDN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | CRVS |
|---|---|---|
| Founded | 1964 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | 2016 |
| Metric | WLDN | CRVS |
|---|---|---|
| Price | $87.00 | $14.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $114.50 | $30.17 |
| AVG Volume (30 Days) | 201.9K | ★ 645.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | 48.04 |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $273,352,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.05 | N/A |
| P/E Ratio | $40.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $64.67 | $5.64 |
| 52 Week High | $137.00 | $26.95 |
| Indicator | WLDN | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 47.02 |
| Support Level | $72.52 | $14.07 |
| Resistance Level | $88.72 | $16.66 |
| Average True Range (ATR) | 2.85 | 0.61 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 74.81 | 18.41 |
Willdan Group Inc is a technical services company focused on energy and infrastructure solutions. The company's solutions include energy planning and analytics, consulting, software, public finance, engineering, and program implementation. It operates through two segments: i) Energy segment: It provides specialized, comprehensive energy solutions to businesses, utilities, state agencies, municipalities, and non-profit organizations. ii) Engineering & Consulting: It provides civil engineering and construction management, building and safety services, city engineering and planning support, civil design, geotechnical services, and material testing. The majority of revenue is derived from the Energy segment. Geographically, all of the company's revenue is generated from the United States.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.